Long-Term Study Reveals Low Dose Aspirin Has No Impact on Cancer Risk for Older Adults

New Study Challenges Aspirin Use for Cancer Prevention in Older Adults

Aspirin Therapy and Cancer Risk

A recent follow-up study has concluded that low-dose aspirin therapy does not effectively reduce the overall cancer risk in older adults. The research indicates that participants who were assigned to receive aspirin experienced a higher risk of cancer-related mortality throughout the trial. Importantly, the study also found that there were no long-term effects on cancer risk after participants ceased taking aspirin.

Recommendations Against Aspirin for Cancer Prevention

The findings of this study suggest that aspirin therapy should not be pursued as a preventive measure against cancer in older adults. Aspirin, widely recognized for its ability to alleviate pain and reduce fever, is also noted for its potential cardiovascular benefits. However, the Food and Drug Administration (FDA) advises that the use of aspirin for these purposes should only occur under medical supervision.

Guidelines from Health Authorities

The US Preventive Services Task Force (USPSTF) guidelines further recommend against initiating low-dose aspirin use in individuals over 60 years of age. With the global population aging, the prevalence of age-related conditions, including cancer, is rising. Over two-thirds of all new cancer diagnoses occur in those aged 60 and older, highlighting the urgent need for effective preventive strategies.

Conflicting Research on Aspirin’s Role

Previous studies have indicated that aspirin might play a role in lowering cancer incidence and mortality, specifically for colorectal and liver cancers. Nonetheless, there is conflicting evidence that suggests potential adverse effects of aspirin for older adults diagnosed with cancer.

Conclusion of the Latest Study

The recent long-term follow-up study published in JAMA Oncology reinforces the notion that aspirin therapy for cancer prevention is not advisable for older adults. The results reveal that aspirin neither reduces cancer risk nor does it benefit overall mortality rates during treatment.